"AnlinkBio" completed a Series A financing of 42 million US dollars.

36Kr has learned that according to the official WeChat account of Gaorong Capital Ventures, "AnlinkBio" announced the completion of a Series A financing round of $42 million. This round of financing is led by BlueRun Ventures, with co-investors including Biospring Ventures, Legend Capital, C&D Emerging Investment, while also receiving additional investments from the existing shareholders Gaorong Capital Ventures and M31 Capital. This round of financing will help accelerate AnlinkBio's global layout, including promoting the Phase I clinical studies of its core pipelines ALK201 and ALK202 in Australia, the United States, and China, actively expanding the R&D pipelines in the fields of oncology and immunology, and continuously optimizing its self-developed bispecific antibody and ADC technology platform.